Enprofylline Inhibitor

Enprofylline, a bronchodilator, acts primarily as a competitive nonselective phosphodiesterase inhibitor. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of sickle cell disease, diabetic neuropathy, and cerebrovascular insufficiency.

Mojsilovic-Petrovic J, Arneja A, Kalb RG. Enprofylline protects motor neurons from in vitro excitotoxic challenge. Neurodegener Dis. 2005;2(3-4):160-5. PubMed PMID: 16909021.
Feoktistov I, Biaggioni I. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest. 1995 Oct;96(4):1979-86. PubMed PMID: 7560091; PubMed Central PMCID: PMC185836.
Chapman KR, Ljungholm K, Kallen A. Long-term xanthine therapy of asthma. Enprofylline and theophylline compared. International Enprofylline Study Group. Chest. 1994 Nov;106(5):1407-13. PubMed PMID: 7956392.
Nadai M, Hasegawa T, Wang L, Tagaya O, Nabeshima T. Alterations in the pharmacokinetics and protein binding of enprofylline in Eisai hyperbilirubinemic rats. Drug Metab Dispos. 1994 Jul-Aug;22(4):561-5. PubMed PMID: 7956730.

Small volumes of Enprofylline, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5756726 is an inhibitor targeting Enprofylline.